


95/95  
BY 2025



# HIDDEN CRISIS




HOW 150 PEOPLE DIE EVERY HOUR FROM FUNGAL INFECTION WHILE THE WORLD TURNS A BLIND EYE







For more information  
visit: [gaffi.org](http://gaffi.org)

# Serious Fungal Infections. The size of the problem



## HIV/AIDS 2016






## TUBERCULOSIS AND TB-LIKE FUNGAL DISEASES



## CANCER AND FUNGAL INFECTIONS




## EYE INFECTIONS (FUNGAL KERATITIS)




Visual recovery with Natamycin drops

## NEGLECTED TROPICAL FUNGAL DISEASES



# GAFFI. Action Plan 2018-2025



One of our educational partners



Microscopy and histology course in English, Spanish, French and Portuguese at: [microfungi.net](http://microfungi.net)



Education through LIFE in English and Spanish at: [life-worldwide.org](http://life-worldwide.org)





# GAFFI in action. A Case Study

## Minimising AIDS deaths through rapid fungal diagnosis and better care in Guatemala

At least 280,000 Guatemalans suffer from a serious fungal infection per year of which an estimated 4,790 are immediately life threatening.

### 01 GAFFI's project has taken off - Diagnostics in place

GAFFI's national project has brought the key mycology diagnostic tests into Guatemala, through the NGO 'Asociación de Salud Integral' (ASI) (<http://www.asi.org.gt>) which offers them to all 16 HIV comprehensive care units. Sample transport from around the country takes 24/48 hours to ASI. Tests are requested from any mobile device and reported back electronically.

### 02 All antifungals now available

GAFFI's national project has ensured availability of key antifungal drugs in all HIV units to treat AIDS related and opportunistic infections.

### 03 Educating the doctors


Meetings, webinars and clinical experience of better diagnostics is empowering local doctors to recognise fungal disease early. Continuing education through the portal (<http://fungired.gt/>) is paying off.

### 04 Impact in the first 6 months of 2017

In the first 6 months of 2017, 2,655 samples were submitted from 1243 patients with AIDS - 139 (11%) tested positive. Pneumocystis PCR will be introduced in 2017, which will increase diagnostic yield. Rapid, accurate fungal disease diagnosis will save many lives, as the treatment of fungal disease is well established. Detailed data collection is ongoing to document the individual patient and public health impact of the program.

### 05 National and hospital advocacy to expand the reach of the program


Expansion of the program to non-AIDS patients is under discussion. The Health Ministry and AIDS Public Health have been petitioned to recognise ASI as an official Mycology Reference Laboratory for AIDS-related fungal opportunistic diseases. Support from the regional office of Pan-American Health Organisation (PAHO) and regional office of Centres for Disease Control (CDC) is valued and will highlight this program as an exemplar for the region.



### Case Study Before and after 6 months antifungal therapy




Blastomycosis before treatment



Lab diagnosis



After treatment



95/95  
BY 2025

## WHAT IMPACT HAS GAFFI HAD SINCE 2013?

- Developed national diagnostic programs in Guatemala, Kenya and Uganda - these are world first's
- Developed a 10 year global Roadmap for improving fungal disease diagnosis and management (95-95 by 2025)
- Shown that 1,600,000 lives could be saved from fungal infections in AIDS with 60% coverage of fungal diagnostics & drugs
- Pushed for 5 antifungal agents being accepted onto the WHO Essential Medicines List (adult and child)
- Estimated the burden of serious fungal diseases in 71 countries (>80% of the global population)
- Published the lack of availability and huge price variations for all 6 critical antifungals
- Persuaded the WHO to include chromblastomycosis and other tropical fungal diseases to be on the Neglected Tropical Disease list
- Argued the case for fungal diagnostics being a key component in fighting antimicrobial resistance (AMR)

### **GAFFI has:**

A worldwide network of country Ambassadors with real expertise.

### **GAFFI has:**

Greatly increased awareness of the global problem of fungal disease and its size.

### **GAFFI is:**

Actively working with diagnostic and pharma companies to increase access to life-saving diagnostics and medicines for low and medium income countries in all continents.

**GAFFI IS THE ONLY GLOBAL NGO FOCUSSED EXCLUSIVELY ON FUNGAL DISEASES**

---

For more information visit: [gaffi.org](http://gaffi.org)

## GAFFI. GLOBAL ACTION FUND FOR FUNGAL INFECTIONS

Over **400,000** people develop Pneumocystis pneumonia in AIDS and always die without therapy. High dose cotrim therapy is available, cheap and effective. The diagnosis is too often missed - no access to testing.

Over **135 MILLION** women suffer from recurrent yeast infection (thrush) each year - with much discomfort, anxiety and productivity loss - a hugely under-appreciated problem.

Nearly a **BILLION** people have a Fungal Infection of the skin, the 3rd most common illness on earth, after headaches and dental caries.

---

## YOU CAN REDUCE ILLNESS AND DEATH ASSOCIATED WITH FUNGAL DISEASES

### PLEASE DONATE

GAFFI requires substantial funding to deliver its mission. Current fund raising is focused on major donor agencies and philanthropists from any country.

If you want to make a contribution to GAFFI's work please go to our website and click on Donate.

Thank you.

### OUR VISION

Our vision is to reduce illness and death associated with fungal diseases worldwide.

### OUR MISSION

Reaching the poor and vulnerable through access to tests and anti-fungal drugs.



To address these issues  
GAFFI has a 10 year roadmap  
'95/95 by 2025'

95/95  
BY 2025

---

Fungal diseases illustrated on front cover (from top left): Chromoblastomycosis in PNG, blind from Candida endophthalmitis in UK, Aspergillus niger onychomycosis in Korea (PMC3505779), disseminated histoplasmosis in Guatemala, fungal keratitis in Greece, fluconazole resistant oropharyngeal candidiasis in UK, Aspergillus osteomyelitis in UK, tinea capitis in Kenya and cutaneous coccidioidomycosis in USA.

### GAFFI

Rue de l'Ancien-Port 14 Case postale 1568,  
1211 Geneva 1, Switzerland

Bridge House, Ashley Road, Hale,  
Altrincham WA14 2UT, UK

Email: [info@gaffi.org](mailto:info@gaffi.org)

